These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32340775)

  • 41. Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules.
    Khodadi E
    Cardiovasc Toxicol; 2020 Feb; 20(1):1-10. PubMed ID: 31784932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Platelet turnover in atherothrombotic disease.
    Lordkipanidzé M
    Curr Pharm Des; 2012; 18(33):5328-43. PubMed ID: 22724418
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.
    Schrottmaier WC; Kral JB; Badrnya S; Assinger A
    Thromb Haemost; 2015 Aug; 114(3):478-89. PubMed ID: 25904241
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
    Maree AO; Fitzgerald DJ
    Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
    [No Abstract]   [Full Text] [Related]  

  • 45. Regulation of Platelet Activation and Coagulation: Current Concepts, Novel Targets, and Therapies.
    Harm T; Lydia Mueller KA; Geisler T
    Interv Cardiol Clin; 2024 Oct; 13(4):451-467. PubMed ID: 39245546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Future Cardiol; 2015 Sep; 11(5):547-64. PubMed ID: 26406386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Platelets in atherothrombosis--diagnostic and prognostic value of platelet activation in patients with atherosclerotic diseases.
    Bigalke B; Schuster A; Sopova K; Wurster T; Stellos K
    Curr Vasc Pharmacol; 2012 Sep; 10(5):589-96. PubMed ID: 22338574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. P2 receptors, platelet function and pharmacological implications.
    Gachet C
    Thromb Haemost; 2008 Mar; 99(3):466-72. PubMed ID: 18327393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
    Liao CH; Ko FN; Wu CL; Teng CM
    J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of platelets in acute kidney injury.
    Jansen MPB; Florquin S; Roelofs JJTH
    Nat Rev Nephrol; 2018 Jul; 14(7):457-471. PubMed ID: 29760447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor.
    Ward JR; Bingle L; Judge HM; Brown SB; Storey RF; Whyte MK; Dower SK; Buttle DJ; Sabroe I
    Thromb Haemost; 2005 Oct; 94(4):831-8. PubMed ID: 16270639
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of antiplatelet agents in sepsis: a glimpse into the future.
    Akinosoglou K; Alexopoulos D
    Thromb Res; 2014 Feb; 133(2):131-8. PubMed ID: 24103487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Mechanisms of platelet activation and development of antiplatelet agents].
    Cazenave JP; Gachet C; Lanza F
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1501-6. PubMed ID: 9092410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents.
    Angiolillo DJ; Ferreiro JL
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):233-50. PubMed ID: 23613159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients.
    Muñoz-Esquerre M; Ferreiro JL; Huertas D; Marcano AL; López-Sánchez M; Roura G; Gómez-Hospital JA; Dorca J; Cequier A; Santos S
    Int J Chron Obstruct Pulmon Dis; 2018; 13():141-148. PubMed ID: 29343953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiplatelet therapy in patients with diabetes mellitus.
    Grove EL; Gregersen S
    Curr Vasc Pharmacol; 2012 Jul; 10(4):494-505. PubMed ID: 22272895
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel Antiplatelet Agents in Cardiovascular Disease.
    Tscharre M; Michelson AD; Gremmel T
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiplatelet effects of some aporphine and phenanthrene alkaloids in rabbits and man.
    Teng CM; Hsueh CM; Chang YL; Ko FN; Lee SS; Liu KC
    J Pharm Pharmacol; 1997 Jul; 49(7):706-11. PubMed ID: 9255715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiplatelet effect of phloroglucinol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production.
    Chang MC; Chang HH; Chan CP; Chou HY; Chang BE; Yeung SY; Wang TM; Jeng JH
    Toxicol Appl Pharmacol; 2012 Sep; 263(3):287-95. PubMed ID: 22789837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Our expanding view of platelet functions and its clinical implications.
    Ombrello C; Block RC; Morrell CN
    J Cardiovasc Transl Res; 2010 Oct; 3(5):538-46. PubMed ID: 20661787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.